GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wuhan Hiteck Biological Pharma Co Ltd (SZSE:300683) » Definitions » Net Income Including Noncontrolling Interests

Wuhan Hiteck Biological Pharma Co (SZSE:300683) Net Income Including Noncontrolling Interests : ¥-140.8 Mil (TTM As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Wuhan Hiteck Biological Pharma Co Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Wuhan Hiteck Biological Pharma Co's Net Income Including Noncontrolling Interests for the three months ended in Sep. 2024 was ¥-17.8 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-140.8 Mil.

Wuhan Hiteck Biological Pharma Co Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Wuhan Hiteck Biological Pharma Co's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Hiteck Biological Pharma Co Net Income Including Noncontrolling Interests Chart

Wuhan Hiteck Biological Pharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.19 -25.68 30.02 -7.90 -128.24

Wuhan Hiteck Biological Pharma Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.80 -98.63 -17.49 -6.95 -17.76

Wuhan Hiteck Biological Pharma Co Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-140.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan Hiteck Biological Pharma Co Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Wuhan Hiteck Biological Pharma Co's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan Hiteck Biological Pharma Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wuhan Hiteck Biological Pharma Co Ltd (SZSE:300683) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
SHSE:603367 SZSE:002437 SZSE:002793 SZSE:301089 SHSE:688553 SZSE:301509 SZSE:301211 SHSE:605199 SHSE:600351 SHSE:600789 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
Hite Science and Technology Park, Wuhan Economic and Technological Development Zone, Hubei Province, Wuhan, CHN, 430056
Website
http://www.hiteck.com.cn
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.
Executives
Yan Jie Director
Li Sheng Qiang Executives

Wuhan Hiteck Biological Pharma Co Headlines

No Headlines